ADVANCED MATERIALS & NANOTECHNOLOGY: RECENT ADVANCES, APPLICATIONS AND FUTURE PERSPECTIVES

Advanced materials and nanotechnology have become important areas of pharmaceutical, biomedical and healthcare research. The development of materials with controlled size, composition, surface properties and functionality has created new opportunities for drug delivery, diagnosis, tissue engineering and therapeutic applications. This review discusses the fundamental concepts of advanced materials and nanotechnology, their classification, preparation methods, characterization techniques, pharmaceutical applications, advantages, limitations, safety considerations and future perspectives. Particular attention is given to polymeric nanoparticles, lipid nanoparticles, liposomes, metallic nanoparticles, magnetic nanoparticles, dendrimers, nanogels, smart biomaterials and biomimetic systems. Nanotechnology can improve drug solubility, stability, bioavailability, controlled release and targeted delivery, while also enabling applications in cancer therapy, gene delivery, vaccines, diagnostics, tissue engineering and theranostics. However, toxicity, reproducibility, scale-up, characterization, long-term stability and regulatory requirements remain important challenges. Future progress will depend on multidisciplinary research, standardized characterization, quality-by-design approaches and robust safety evaluation.

• U.S. Food and Drug Administration. Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry. FDA, 2022.
• U.S. Food and Drug Administration. Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology: Guidance for Industry. FDA, 2014.
• U.S. Food and Drug Administration. Considerations for Drug Products that Contain Nanomaterials. FDA, 2023.
• National Nanotechnology Initiative. Nanotechnology: Understanding and Control of Matter at the Nanoscale.
• ISO. Nanotechnologies—Vocabulary: ISO/TS 80004 series. International Organization for Standardization.
• Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases, 2007; 2: MR17–MR71.
• De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine, 2008; 3: 133–149.
• Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science, 2006; 311:    622–627.
• Oberdörster G, Stone V, Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology, 2009; 3: 2–7.
• Pautler M, Brenner S. Nanomedicine: promises and challenges. J Clin Pharm Ther., 2010; 35: 2–8.
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol, 2007; 2: 751–760.
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev., 2013; 65: 36–48.
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov., 2005; 4: 145–160.
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine, 2015; 10: 975–999.
• Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol, 2015; 6: 286.
• Beach MA, Nayanathara U, Gao Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev., 2024; 124: 5505–5616.
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 2001; 70: 1–20.
• Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev., 2012; 41:           2740–2779.
• Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv., 2009; 27: 76–83.
• Bose S, Roy M, Bandyopadhyay A. Recent advances in bone tissue engineering scaffolds. Trends Biotechnol, 2012; 30: 546–554.
• Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 2011; 3: 1377–1397.
• Stuart MAC, Huck WTS, Genzer J, et al. Emerging applications of stimuli-responsive polymer materials. Nat Mater, 2010; 9: 101–113.
• Begines B, et al. Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials, 2020.
• Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev., 2012; 41: 2545–2561.
• Puri A, et al. Liposomal nanotechnology for drug delivery. Crit Rev Ther Drug Carrier Syst., 2009; 26: 523–580.
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med., 2012; 63: 185–198.
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol, 2015; 33: 941–951.
• Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med., 2016; 1: 10–29.
• Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov., 2021; 20: 101–124.
• Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer, 2017; 17: 20–37.
• Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials. Pharm Res., 2016; 33: 2373–2387.
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale and clinical applications. Int J Nanomedicine, 2006; 1: 297–315.
• Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev., 2015; 115: 10938–10966.
• Edwards K, Baeumner AJ. Liposomes in analyses. Talanta, 2006; 68: 1432–1441.
• Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater., 2021; 6: 1078–1094.
• Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther., 2018; 28: 146–157.
• Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther., 2017; 25:   1467–1475.
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles for controlled drug delivery. Eur J Pharm Biopharm, 2000; 50: 161–177.
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles and nanostructured lipid carriers. Adv Drug Deliv Rev., 2002; 54: S131–S155.
• Mehmood S, Iraqui S, Ojha RK, et al. Therapeutic potential and toxicological challenges of metal nanoparticles in drug delivery. Nanomedicine, 2025; 70: 102862.
• Laurent S, Forge D, Port M, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations and biological applications. Chem Rev., 2008; 108: 2064–2110.
• Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles: development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev., 2011; 63: 24–46.
• Yip LX, Wang J, Xue Y, et al. Cell-derived nanomaterials for biomedical applications. Sci Technol Adv Mater., 2024; 25: 2315013.
• Tang K, Xue J, Zhu Y, Wu C. Design and synthesis of bioinspired nanomaterials for biomedical application. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2023. DOI:10.1002/wnan.1914.
• Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev., 2005; 57: 2106–2129.
• Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. Polymer, 2008; 49:         1993–2007.
• Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm., 1989; 55: R1–R4.
• Müller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs. J Biotechnol, 2004; 113: 151–170.
• Kentish S, Wooster TJ. Lipid nanoparticle formation using ultrasound. Curr Opin Colloid Interface Sci., 2010; 15: 121–126.
• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release, 2004; 100: 5–28.
• Karnik R, Gu F, Basto P, et al. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett., 2008; 8: 2906–2912.
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev., 2001; 47: 165–196.
• Whitesides GM. Self-assembly at all scales. Science, 2002; 295: 2418–2421.
• Filippov SK, et al. Dynamic light scattering and transmission electron microscopy in drug delivery: a roadmap for correct characterization of nanoparticles and interpretation of results. Mater Horiz., 2023; 10: 5354–5370.
• Pham SH, et al. Characterization of nanoparticles for drug delivery applications. Nanomedicine, 2016.
• Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems. Trop J Pharm Res., 2013; 12: 255–264.
• Coates J. Interpretation of infrared spectra: a practical approach. Encyclopedia of Analytical Chemistry, 2000.
• Cullity BD, Stock SR. Elements of X-Ray Diffraction. 3rd ed. Pearson, 2001.
• Gill P, Moghadam TT, Ranjbar B. Differential scanning calorimetry techniques: applications in biology and nanoscience. J Biomol Tech., 2010; 21: 167–193.
• Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Wiley, 2010.
• Briggs D, Seah MP. Practical Surface Analysis: Auger and X-ray Photoelectron Spectroscopy. Wiley, 1990.
• Cullity BD, Graham CD. Introduction to Magnetic Materials. 2nd ed. Wiley-IEEE, 2008.
• Junghanns JUA, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine, 2008; 3: 295–309.
• Müller RH, Keck CM. Twenty years of drug nanocrystals: where are we, and where do we go? Eur J Pharm Biopharm, 2012; 80: 1–3.
• Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev., 2012; 64: 302–315.
• Ruoslahti E. Peptides as targeting elements and tissue penetration devices. Adv Mater, 2012; 24: 3747–3756.
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2002; 2:          750–763.
• Chourasia MK, et al. Nanotechnology assisted drug delivery strategies for chemotherapy: recent advances and future prospects. ACS Appl Bio Mater, 2025.
• Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev., 2012; 41:      2740–2779.
• Estelrich J, Escribano E, Queralt J, Busquets MA. Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. Int J Mol Sci., 2015; 16: 807–838.
• Mamaeva V, Sahlgren C, Lindén M. Mesoporous silica nanoparticles in medicine—recent advances. Adv Drug Deliv Rev., 2013; 65: 689–702.
• Irvine DJ, Dane EL. Enhancing cancer vaccines with nanotechnology. Nat Rev Immunol, 2020; 20:     321–334.
• Shaw TK, Shuvo SM, Paul P, et al. Cutting-edge strategies for delivering drugs to the brain based on nanocarriers. Drug Dev Ind Pharm., 2025; 51:  1625–1638.
• Wu Y, Liu P, Mehrjou B, Chu PK. Interdisciplinary-inspired smart antibacterial materials and their biomedical applications. Adv Mater., 2024; 36: e2305940.
• Cecen B, Hassan S, Li X, Zhang YS. Smart biomaterials in biomedical applications: current advances and possible future directions. Adv Healthc Mater, 2024.
• Fatima M, Almalki WH, Khan T, et al. Harnessing the power of stimuli-responsive nanoparticles as an effective therapeutic drug delivery system. Adv Mater., 2024; 36: e2312939.
• Gobinath M, Mukherjee S, Soundarya R, et al. Nanotechnology-enabled pharmaceuticals and biomaterials: innovations in drug delivery, theranostics, and clinical translation. Life Sci X., 2026; Article 100528.
• Ashraf M, Zulfiqar F, Ijaz U, et al. Nanotechnology, nano-systems and applications of nanoparticles in novel drug delivery—a comprehensive review. Pak J Pharm Sci., 2025; 38(2): 669–677.
• Kuskov AN, Kukovyakina EV. Nanotechnology-based drug delivery systems, 2nd edition. Pharmaceutics, 2025; 17(1): 110.
• Ammar MM, Ali R, Abd Elaziz NA, et al. Nanotechnology in oncology: advances in biosynthesis, drug delivery, and theranostics. Discov Oncol, 2025; 16: 1172.